Menu Search
Equities

Mabion SA

272:STU

Mabion SA

Actions
  • Price (EUR)3.78
  • Today's Change-0.055 / -1.43%
  • Shares traded0.00
  • 1 Year change+1.94%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mabion SA is a Poland-based company primarily engaged in research and experimental development on natural sciences and engineering. The Company is the precursor of the biotechnology sector in Central Europe. The Company specializes in the production of sterile biotechnological products in a manufacturing plant that meets the requirements of Good Manufacturing Practice (GMP). The Company integrates and commercializes scientific achievements in order to develop a biological medicinal substance based on mammalian cell cultures. The Company participates in projects by combining scientific knowledge and advanced technology to develop products and processes. The Company provides its business partners with the biotechnological solutions and gives the patients access to the next generation of therapeutics.

  • Revenue in PLN (TTM)139.86m
  • Net income in PLN37.39m
  • Incorporated2009
  • Employees226.00
  • Location
    Mabion SAgen. Mariana Langiewicza 60KONSTANTYNOW LODZKI 95-050PolandPOL
  • Phone+48 422077890
  • Fax+48 422032703
  • Websitehttps://www.mabion.eu/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.